LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

238.37 -1.01

Buy Sell

Overview

Share price change

24h

Current

Min

231.63

Max

248.01

Key metrics
By Trading Economics
Income	28M -33M
Sales	32M 245M
Profit margin	-13.56
Employees	1,189
EBITDA	68M 15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+18.72% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	856M 14B
Previous open	239.38
Previous close	238.37

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 mar 2026, 18:43 UTC

Major News Events

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3 mar 2026, 17:33 UTC

Acquisitions, Mergers, Takeovers

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3 mar 2026, 23:45 UTC

Market Talk

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3 mar 2026, 23:44 UTC

Market Talk

Major News Events

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3 mar 2026, 23:25 UTC

Market Talk

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3 mar 2026, 23:25 UTC

Market Talk

Global Energy Roundup: Market Talk

3 mar 2026, 22:38 UTC

Major News Events

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3 mar 2026, 22:16 UTC

Earnings

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3 mar 2026, 22:09 UTC

Earnings

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3 mar 2026, 22:06 UTC

Earnings

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3 mar 2026, 22:05 UTC

Earnings

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3 mar 2026, 22:03 UTC

Earnings

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3 mar 2026, 21:50 UTC

Market Talk

Major News Events

Tech, Media & Telecom Roundup: Market Talk

3 mar 2026, 21:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

3 mar 2026, 21:45 UTC

Major News Events

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3 mar 2026, 21:37 UTC

Earnings

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3 mar 2026, 21:26 UTC

Major News Events

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3 mar 2026, 20:31 UTC

Market Talk

Major News Events

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3 mar 2026, 20:04 UTC

Market Talk

Major News Events

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3 mar 2026, 19:17 UTC

Market Talk

Major News Events

Gold and Silver Drop as Energy Surges -- Market Talk

3 mar 2026, 18:43 UTC

Earnings

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3 mar 2026, 18:29 UTC

Market Talk

Major News Events

Global Energy Roundup: Market Talk

3 mar 2026, 18:29 UTC

Market Talk

Major News Events

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3 mar 2026, 18:22 UTC

Major News Events

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3 mar 2026, 18:22 UTC

Major News Events

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3 mar 2026, 18:17 UTC

Market Talk

Major News Events

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3 mar 2026, 18:14 UTC

Earnings

How Long Can Anthropic Play Defense? -- WSJ

3 mar 2026, 17:41 UTC

Major News Events

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3 mar 2026, 17:36 UTC

Major News Events

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3 mar 2026, 17:28 UTC

Acquisitions, Mergers, Takeovers

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

18.72% upside

12 Months Forecast

Average 287.42 USD 18.72%

High 342 USD

Low 250 USD

Based on 12 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.